Exatecan

Summary

Exatecan (CHEMBL1614650) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Clinical trials: 16
• Chemistry: 435.4 Da · C24H22FN3O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1614650
Name	Exatecan
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	151115
Molecular formula	C24H22FN3O4
Molecular weight	435.4
InChIKey	ZVYVPGLRVWUPMP-FYSMJZIKSA-N

SMILES: CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C5[C@H](CCC6=C5C(=CC(=C6C)F)N=C4C3=C2)N)O

IUPAC name: (10S,23S)-23-amino-10-ethyl-18-fluoro-10-hydroxy-19-methyl-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptaene-5,9-dione

Also known as: DX-8951, Exatecan, DX8951f, Exatecan Mesylate, EXATECAN

Parent form; salt/anhydrous children: CHEMBL3989759

Patent coverage: 637 distinct patent families (1,339 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 953 (71%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 16.

Phase distribution

Phase	Trials
PHASE2	12
PHASE1	3
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00023972	PHASE3	COMPLETED	Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
NCT00003951	PHASE2	COMPLETED	DX-8951f in Treating Patients With Metastatic Cancer of the Pancreas
NCT00004045	PHASE2	COMPLETED	Chemotherapy in Treating Patients With Prostate Cancer
NCT00004046	PHASE2	COMPLETED	Chemotherapy in Treating Women With Metastatic Breast Cancer
NCT00004060	PHASE2	COMPLETED	Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT00004108	PHASE2	COMPLETED	DX-8951f in Treating Patients With Liver Cancer
NCT00004866	PHASE2	COMPLETED	DX-8951f in Treating Women Who Have Advanced or Recurrent Cancer of the Cervix
NCT00005091	PHASE2	COMPLETED	DX-8951f in Treating Previously Untreated Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
NCT00005938	PHASE2	COMPLETED	DX-8951f in Treating Patients With Biliary Cancer
NCT00017212	PHASE2	COMPLETED	DX-8951f in Treating Patients With Metastatic Stomach Cancer
NCT00041236	PHASE2	COMPLETED	Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma
NCT00055939	PHASE2	COMPLETED	Exatecan Mesylate in Treating Children With Relapsed or Refractory Rhabdomyosarcoma
NCT00055952	PHASE2	COMPLETED	Exatecan Mesylate in Treating Patients With Ewing’s Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor
NCT00004047	PHASE1	COMPLETED	Chemotherapy in Treating Patients Who Have Hematologic Cancer
NCT00004212	PHASE1	COMPLETED	DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
NCT00045318	PHASE1	COMPLETED	Exatecan Mesylate in Treating Patients With Advanced Solid Tumors and Kidney Dysfunction

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).